Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.00
Bid: 43.00
Ask: 47.00
Change: 0.00 (0.00%)
Spread: 4.00 (9.302%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 47.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

13 Jan 2021 07:00

RNS Number : 4664L
Benchmark Holdings PLC
13 January 2021
 

13 January 2021

Benchmark Holdings plc

("Benchmark" or "the Company")

Payment of contingent consideration following achievement of milestones

 

Issue of Equity

 

Benchmark (AIM: BMK), the aquaculture health, nutrition and genetics business, announces that further to the acquisition of aquaculture breeding programmes centred on shrimp from Centro de Investigación de la Acuicultura de Colombia Ceniacua on 11 August 2016, $450,000 of contingent consideration is payable following the satisfaction of specified operational milestones (the "Contingent Consideration").

At the Company's discretion, the Contingent Consideration is payable in ordinary shares in the Company using an agreed formula. The Company has therefore issued 536,272 Ordinary Shares of 0.1p each in the capital of the Company (the "New Ordinary Shares").

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading will commence at 8:00am on 18 January 2021. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 668,927,771. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Trond Williksen, CEO, commented:

 

"The payment of the contingent consideration is a reflection of the success of our shrimp genetics operations since the acquisition was made. Through a team of leading geneticists, we successfully expanded our genetics business into shrimp and developed a Specified Pathogen Resistant SPR shrimp which will be rolled out in Asia in the coming year.

 

"Specialist genetics are a significant driver of sustainable production. The introduction of SPR shrimp will help improve sustainability in shrimp production and is an important growth vector for Benchmark, as we remain focused on becoming a profitable, cash generative Group."

 

 Enquiries

For further information, please contact:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

 

Septima Maguire, CFO

 

Ivonne Cantu, Investor Relations

 

 

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

 

 

 

MHP Communications

Tel: 020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver, Charlie Protheroe

benchmark@mhpc.com

 

 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFEFUEEFSEFF
Date   Source Headline
28th Jan 20198:00 amRNSDIRECTOR SHARE OPTIONS
24th Jan 20197:00 amRNSFull Year Results
14th Jan 20197:00 amRNSNotice of Results
31st Dec 20188:00 amRNSTotal Voting Rights
12th Dec 20183:08 pmRNSDirector/PDMR Shareholding
12th Dec 201811:01 amRNSHolding(s) in Company
10th Dec 20185:05 pmRNSHolding(s) in Company
7th Dec 20183:35 pmRNSHolding(s) in Company
30th Nov 20187:00 amRNSTotal Voting Rights
30th Nov 20187:00 amRNSTotal Voting Rights
27th Nov 20187:00 amRNSSuccessful defence of patent infringement in Asia
7th Nov 20187:00 amRNSTrading Statement
31st Oct 20187:00 amRNSTotal Voting Rights
23rd Oct 20184:55 pmRNSHolding(s) in Company
22nd Oct 20185:52 pmRNSHolding(s) in Company
10th Oct 20182:53 pmRNSDIRECTOR DEALINGS
3rd Oct 20187:00 amRNSAcquisition and Issue of Equity
2nd Oct 20187:00 amRNSAppointment of Chief Scientific Officer
28th Sep 20187:00 amRNSTotal Voting Rights
21st Sep 20187:00 amRNSBlock listing Interim Review
12th Sep 20187:00 amRNSBlock Admission Application
10th Sep 20187:00 amRNSCommencement of salmon egg production in Salten
30th Aug 20187:00 amRNSTotal Voting Rights
30th Jul 20187:00 amRNSTotal Voting Rights
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company
22nd Jun 20184:31 pmRNSHolding(s) in Company
22nd Jun 20187:00 amRNSDIRECTOR DEALINGS
19th Jun 20184:06 pmRNSUpdate on Joint Venture and Placing
19th Jun 20187:00 amRNSInterim Results
8th Jun 20187:00 amRNSJoint Venture, Placing and Trading Update
31st May 20187:00 amRNSTotal Voting Rights
8th May 20187:00 amRNSAppointment of Chairman
30th Apr 201812:23 pmRNSTotal Voting Rights
9th Apr 201811:14 amRNSHolding(s) in Company
5th Apr 20183:58 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
27th Mar 20187:00 amRNSBenchmark hosts Capital Markets Day today
21st Mar 20187:00 amRNSBlock listing six monthly return
8th Mar 20181:37 pmRNSResult of AGM
7th Feb 20189:05 amRNSDirector Dealings
31st Jan 20187:00 amRNSBoard Succession
31st Jan 20187:00 amRNSTotal Voting Rights
25th Jan 201811:54 amRNSDirector Share Options
24th Jan 20183:17 pmRNSHolding(s) in Company
24th Jan 20181:01 pmRNSDirector Dealings
24th Jan 20187:00 amRNSPosting of Annual Report & Notice of AGM
23rd Jan 20187:08 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.